PT3429591T - Derivados de tieno[2,3-d]pirimidina substituídos como inibidores de menina-llm e métodos de utilização - Google Patents
Derivados de tieno[2,3-d]pirimidina substituídos como inibidores de menina-llm e métodos de utilizaçãoInfo
- Publication number
- PT3429591T PT3429591T PT177674629T PT17767462T PT3429591T PT 3429591 T PT3429591 T PT 3429591T PT 177674629 T PT177674629 T PT 177674629T PT 17767462 T PT17767462 T PT 17767462T PT 3429591 T PT3429591 T PT 3429591T
- Authority
- PT
- Portugal
- Prior art keywords
- menin
- mll
- methods
- substituted inhibitors
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662309372P | 2016-03-16 | 2016-03-16 | |
| US201662334369P | 2016-05-10 | 2016-05-10 | |
| US201662431389P | 2016-12-07 | 2016-12-07 | |
| US201762446640P | 2017-01-16 | 2017-01-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3429591T true PT3429591T (pt) | 2023-06-21 |
Family
ID=59851028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT177674629T PT3429591T (pt) | 2016-03-16 | 2017-03-15 | Derivados de tieno[2,3-d]pirimidina substituídos como inibidores de menina-llm e métodos de utilização |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US10781218B2 (pt) |
| EP (2) | EP4219449A3 (pt) |
| JP (3) | JP6919977B2 (pt) |
| KR (1) | KR102419531B1 (pt) |
| CN (2) | CN114539284A (pt) |
| AU (1) | AU2017232516B2 (pt) |
| BR (1) | BR112018068703B1 (pt) |
| CA (1) | CA3015847A1 (pt) |
| CY (1) | CY1126066T1 (pt) |
| DK (1) | DK3429591T3 (pt) |
| ES (1) | ES2947636T3 (pt) |
| FI (1) | FI3429591T3 (pt) |
| HK (1) | HK1259232A1 (pt) |
| HR (1) | HRP20230537T1 (pt) |
| HU (1) | HUE061989T2 (pt) |
| IL (1) | IL261606B (pt) |
| LT (1) | LT3429591T (pt) |
| MD (1) | MD3429591T2 (pt) |
| MX (1) | MX2018011105A (pt) |
| PH (1) | PH12018501952A1 (pt) |
| PL (1) | PL3429591T3 (pt) |
| PT (1) | PT3429591T (pt) |
| RS (1) | RS64261B1 (pt) |
| SG (1) | SG11201807982UA (pt) |
| SI (1) | SI3429591T1 (pt) |
| TW (1) | TWI747889B (pt) |
| WO (1) | WO2017161028A1 (pt) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112500338A (zh) | 2013-03-15 | 2021-03-16 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| WO2016040330A1 (en) | 2014-09-09 | 2016-03-17 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| US10588907B2 (en) | 2015-06-04 | 2020-03-17 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| KR20180098679A (ko) | 2016-01-22 | 2018-09-04 | 잔센파마슈티카엔.브이. | Nik 억제제로서의 신규 6원 헤테로방향족 치환된 시아노인돌린 유도체 |
| DK3405196T3 (en) | 2016-01-22 | 2020-03-09 | Janssen Pharmaceutica Nv | Nye substituerede cyanoindolinderivater som nik-inhibitorer |
| WO2017161002A1 (en) | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Bridged bicyclic inhibitors of menin-mll and methods of use |
| MX2018011105A (es) | 2016-03-16 | 2018-11-22 | Kura Oncology Inc | Inhibidores sustituidos de menina-mll y metodos de uso. |
| KR20190015275A (ko) | 2016-05-02 | 2019-02-13 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 메닌 억제제로서의 피페리딘 |
| EP3478673B1 (en) | 2016-06-30 | 2020-09-16 | Janssen Pharmaceutica NV | Cyanoindoline derivatives as nik inhibitors |
| EP3478675B1 (en) | 2016-06-30 | 2020-04-22 | Janssen Pharmaceutica NV | Heteroaromatic derivatives as nik inhibitors |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| CN109641899B (zh) | 2016-09-09 | 2022-07-22 | 诺华股份有限公司 | 作为内体Toll样受体抑制剂的化合物及组合物 |
| TWI753016B (zh) | 2016-09-14 | 2022-01-21 | 比利時商健生藥品公司 | Menin-mll相互作用之稠合二環抑制劑 |
| US11220517B2 (en) | 2016-09-14 | 2022-01-11 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| US11008325B2 (en) | 2016-11-14 | 2021-05-18 | Virginia Commonwealth University | Inhibitors of cancer invasion, attachment, and/or metastasis |
| ES2901227T3 (es) | 2016-12-15 | 2022-03-21 | Janssen Pharmaceutica Nv | Inhibidores de azepano de la interacción menina-MLL |
| EA201991448A1 (ru) | 2017-01-06 | 2019-12-30 | Янссен Фармацевтика Нв | Азепановые ингибиторы взаимодействия менин-mll |
| EP3601249A4 (en) * | 2017-03-24 | 2020-12-16 | Kura Oncology, Inc. | METHODS OF TREATMENT OF MALIGNANT HEMOPATHIES AND EWING'S SARCOMA |
| KR20190133224A (ko) | 2017-03-31 | 2019-12-02 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 공유 메닌 억제제로서의 피페리딘 |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| CA3069138A1 (en) | 2017-07-10 | 2019-01-17 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| SG11202000230VA (en) | 2017-07-11 | 2020-02-27 | Vertex Pharma | Carboxamides as modulators of sodium channels |
| TW201920170A (zh) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
| SG11202001684PA (en) | 2017-10-06 | 2020-03-30 | Forma Therapeutics Inc | Inhibiting ubiquitin specific peptidase 30 |
| TWI780511B (zh) | 2017-10-27 | 2022-10-11 | 德商百靈佳殷格翰國際股份有限公司 | Trpc 6抑制劑 |
| TW201927777A (zh) * | 2017-12-19 | 2019-07-16 | 大陸商基石藥業（蘇州）有限公司 | Ido抑制劑 |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| US10836769B2 (en) | 2018-02-26 | 2020-11-17 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| JP7474709B2 (ja) | 2018-02-27 | 2024-04-25 | インサイト・コーポレイション | Ａ２ａ／ａ２ｂ阻害剤としてのイミダゾピリミジン及びトリアゾロピリミジン |
| CN110204552B (zh) * | 2018-02-28 | 2021-08-17 | 中国科学院上海药物研究所 | 一类噻吩并[3,2-d]嘧啶衍生物、其制备方法、药物组合物与用途 |
| IL276802B2 (en) | 2018-03-09 | 2023-09-01 | Recurium Ip Holdings Llc | Transduced 2,1-dihydro-3h-pyrazolo[4,3-d]pyrimidine-3-ones |
| KR20200143376A (ko) | 2018-03-13 | 2020-12-23 | 샤이어 휴먼 지네틱 테라피즈 인크. | 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도 |
| CN112105621B (zh) | 2018-03-30 | 2024-02-20 | 住友制药株式会社 | 光学活性桥型环状仲胺衍生物 |
| TW202012414A (zh) | 2018-04-12 | 2020-04-01 | 美商拓臻股份有限公司 | 三環ask1抑制劑 |
| SI3784663T1 (sl) | 2018-04-23 | 2023-11-30 | Celgene Corporation | Spojine substituiranega 4-aminoizoindolin-1,3-diona in njihova uporaba za zdravljenje limfoma |
| US11168089B2 (en) | 2018-05-18 | 2021-11-09 | Incyte Corporation | Fused pyrimidine derivatives as A2A / A2B inhibitors |
| GEP20237560B (en) | 2018-07-05 | 2023-10-25 | Incyte Corp | Fused pyrazine derivatives as a2a / a2b inhibitors |
| CN112996795A (zh) | 2018-09-18 | 2021-06-18 | 尼坎医疗公司 | 作为src同源-2磷酸酶抑制剂的稠合的三环衍生物 |
| CN113164443A (zh) * | 2018-09-26 | 2021-07-23 | 库拉肿瘤学公司 | 用多发性内分泌抑癌蛋白抑制剂治疗血液***恶性肿瘤 |
| LT3860989T (lt) | 2018-10-05 | 2023-06-12 | Forma Therapeutics, Inc. | Sulieti pirolinai, kurie veikia kaip ubikvitinui specifinės proteazės 30 (ups30) inhibitoriai |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| AU2019382642A1 (en) | 2018-11-22 | 2021-06-10 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| MX2021006696A (es) | 2018-12-06 | 2021-07-07 | Daiichi Sankyo Co Ltd | Derivado de cicloalcano-1,3-diamina. |
| US11174263B2 (en) | 2018-12-31 | 2021-11-16 | Biomea Fusion, Inc. | Inhibitors of menin-MLL interaction |
| MA54758A (fr) | 2019-01-18 | 2022-04-27 | Astrazeneca Ab | Inhibiteurs de pcsk9 et leurs procédés d'utilisation |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及***并吡啶 |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| US11529350B2 (en) | 2019-07-03 | 2022-12-20 | Sumitomo Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof |
| JP2023509260A (ja) | 2019-08-14 | 2023-03-08 | インサイト・コーポレイション | Ｃｄｋ２阻害剤としてのイミダゾリルピリミジニルアミン化合物 |
| US11787796B2 (en) | 2019-09-18 | 2023-10-17 | Takeda Pharmaceutical Company Limited | Plasma Kallikrein inhibitors and uses thereof |
| JP2022549601A (ja) | 2019-09-18 | 2022-11-28 | 武田薬品工業株式会社 | ヘテロアリール血漿カリクレインインヒビター |
| WO2021072232A1 (en) | 2019-10-11 | 2021-04-15 | Incyte Corporation | Bicyclic amines as cdk2 inhibitors |
| JP2022552735A (ja) | 2019-10-25 | 2022-12-19 | ギリアード サイエンシーズ， インコーポレイテッド | Ｇｌｐ－１ｒ調節化合物 |
| KR20220124176A (ko) | 2019-12-06 | 2022-09-13 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 치환된 테트라하이드로푸란 |
| PE20221264A1 (es) | 2019-12-23 | 2022-08-16 | Blueprint Medicines Corp | Inhibidores de egfr |
| WO2021138540A1 (en) | 2020-01-03 | 2021-07-08 | Berg Llc | Polycyclic amides as ube2k modulators for treating cancer |
| TW202322824A (zh) | 2020-02-18 | 2023-06-16 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| CN111297863B (zh) * | 2020-03-30 | 2021-06-25 | 四川大学华西医院 | menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用 |
| KR20230051127A (ko) | 2020-05-15 | 2023-04-17 | 알젠 바이오테크놀로지스, 인크. | 특정 화학 조성물 및 이의 사용 방법 |
| US11851419B2 (en) | 2020-11-20 | 2023-12-26 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| BR112023016590A2 (pt) | 2021-02-19 | 2023-11-14 | Sudo Biosciences Ltd | Inibidores de tyk2 e seus usos |
| EP4323362A1 (en) | 2021-04-16 | 2024-02-21 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
| JP2024514009A (ja) | 2021-04-21 | 2024-03-27 | ギリアード サイエンシーズ， インコーポレイテッド | カルボキシ－ベンズイミダゾールｇｌｐ－１ｒ調節化合物 |
| CN117321049A (zh) | 2021-05-08 | 2023-12-29 | 詹森药业有限公司 | 取代的螺环衍生物 |
| WO2022237627A1 (en) | 2021-05-08 | 2022-11-17 | Janssen Pharmaceutica Nv | Substituted spiro derivatives |
| US20230250096A1 (en) | 2021-06-01 | 2023-08-10 | Janssen Pharmaceutica Nv | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES |
| BR112023025436A2 (pt) | 2021-06-03 | 2024-02-27 | Janssen Pharmaceutica Nv | Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas |
| WO2022253309A1 (zh) * | 2021-06-03 | 2022-12-08 | 首药控股(北京)股份有限公司 | 取代的杂环化合物及其应用 |
| KR20240031300A (ko) | 2021-06-04 | 2024-03-07 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널 조절제로서의 n-(하이드록시알킬 (헤테로)아릴) 테트라하이드로푸란 카르복스아미드 |
| IL309359A (en) | 2021-06-17 | 2024-02-01 | Janssen Pharmaceutica Nv | (R)-N-ethyl-5-fluoro-N-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexane-3-yl)- salt 6,2-diazaspiro[4.3]octan-6-yl)-4,2,1-triazin-6-yl)oxy) benzamide besylate for the treatment of diseases such as cancer |
| CN115515958B (zh) * | 2021-08-04 | 2023-09-29 | 成都苑东生物制药股份有限公司 | 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途 |
| WO2023011446A1 (zh) * | 2021-08-04 | 2023-02-09 | 成都苑东生物制药股份有限公司 | 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途 |
| WO2023150635A1 (en) * | 2022-02-04 | 2023-08-10 | Kura Oncology, Inc. | Treatment of hematological malignancies with menin inhibitors and p-glycoprotein inhibitors |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5863A (en) | 1848-10-17 | Matthias p | ||
| US5861A (en) | 1848-10-17 | Locking umbrella and parasol | ||
| US510A (en) | 1837-12-07 | soeel | ||
| US949A (en) | 1838-09-27 | Improvement in roller cotton-gins for ginning long-staple and other kinds of cotton | ||
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| DE4239169A1 (de) | 1992-11-21 | 1994-05-26 | Merck Patent Gmbh | Cyclobutan - Benzol - Derivate |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| CA2218503C (en) | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
| ATE225343T1 (de) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | Matrix-metalloprotease inhibitoren |
| JP3195756B2 (ja) | 1996-07-04 | 2001-08-06 | 公子 吉水 | 潤滑補助体 |
| DE69712496T2 (de) | 1996-07-18 | 2002-08-29 | Pfizer | Matrix metalloprotease-inhibitoren auf basis von phosphinsäuren |
| KR20000068248A (ko) | 1996-08-23 | 2000-11-25 | 디. 제이. 우드, 스피겔 알렌 제이 | 아릴설포닐아미노 하이드록삼산 유도체 |
| US5866562A (en) | 1996-10-25 | 1999-02-02 | Bayer Aktiengesellschaft | Ring-bridged bis-quinolines |
| PT950059E (pt) | 1997-01-06 | 2004-10-29 | Pfizer | Derivados de sulfona ciclicos |
| US6303636B1 (en) | 1997-02-03 | 2001-10-16 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| AU5493598A (en) | 1997-02-07 | 1998-08-26 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
| BR9807678A (pt) | 1997-02-11 | 2000-02-15 | Pfizer | Derivados de ácidos arilsulfonil-hidroxâmicos |
| JPH10330377A (ja) | 1997-06-02 | 1998-12-15 | Kyowa Hakko Kogyo Co Ltd | ピペリジン誘導体 |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| US6479487B1 (en) | 1998-02-26 | 2002-11-12 | Aventis Pharmaceuticals Inc. | 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| US20070208087A1 (en) | 2001-11-02 | 2007-09-06 | Sanders Virginia J | Compounds, compositions and methods for the treatment of inflammatory diseases |
| EP1382603B1 (en) | 2001-04-26 | 2008-07-23 | Eisai R&D Management Co., Ltd. | Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof |
| CN100343258C (zh) | 2001-04-30 | 2007-10-17 | 美国拜尔公司 | 新的4－氨基－5,6－取代的噻吩并[2,3－d]嘧啶化合物 |
| US7115741B2 (en) | 2001-09-06 | 2006-10-03 | Levy Daniel E | 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds |
| AU2003258662A1 (en) | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4-amino-quinazolines as anti cancer agents |
| AU2003255482A1 (en) | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4 amino-quinazolines as anti cancer agents |
| US20050222175A1 (en) | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| EP1622914B1 (en) | 2003-03-31 | 2011-06-01 | Trovis Pharmaceuticals LLC | New piperidinylamino-thieno[2,3-d] pyrimidine compounds |
| US7612078B2 (en) | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| JP5335191B2 (ja) | 2003-08-22 | 2013-11-06 | デンドレオン コーポレイション | Ｔｒｐ−ｐ８発現に関連する疾患の処置をするための組成物および方法 |
| US20050123906A1 (en) | 2003-11-06 | 2005-06-09 | Rana Tariq M. | Protein modulation |
| CA2573103A1 (en) | 2004-07-06 | 2006-02-09 | Angion Biomedica Corporation | Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer |
| WO2006132914A2 (en) | 2005-06-03 | 2006-12-14 | Abbott Laboratories | Cyclobutyl amine derivatives |
| US20060281769A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators |
| US20060281771A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators |
| MX2008003032A (es) | 2005-09-02 | 2008-03-24 | Tibotec Pharm Ltd | Benzodiazepinas como inhibidores del virus del la hepatitis c. |
| US7744968B2 (en) | 2005-09-19 | 2010-06-29 | Merck Patent Gmbh | Cyclobutane and spiro[3.3]heptane compounds |
| FR2891829A1 (fr) | 2005-10-12 | 2007-04-13 | Sanofi Aventis Sa | Derives de la 4-amino-quinazoline, leur preparation et leur application en therapeutique |
| AR057579A1 (es) | 2005-11-23 | 2007-12-05 | Merck & Co Inc | Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac) |
| CA2633757A1 (en) | 2005-12-21 | 2007-07-05 | Abbott Laboratories | Anti-viral compounds |
| CA2651898A1 (en) | 2006-04-07 | 2007-10-18 | Develogen Aktiengesellschaft | Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions |
| EP1903044A1 (en) * | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
| WO2008070303A2 (en) | 2006-10-19 | 2008-06-12 | The University Of Chicago | Therapeutics to inhibit mll-menin interaction for treating leukemia |
| EP1947103A1 (en) | 2007-01-22 | 2008-07-23 | 4Sc Ag | Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments |
| WO2008099019A1 (en) | 2007-02-16 | 2008-08-21 | Tibotec Pharmaceuticals Ltd. | 6-hydroxy-dibenzodiazepinones useful as hepatitis c virus inhibitors |
| FR2913017A1 (fr) | 2007-02-23 | 2008-08-29 | Cerep Sa | Derives de piperidine et piperazine comme agents anti-neoplasiques ou inhibiteurs de proliferation cellulaire |
| EP2150527B1 (en) | 2007-03-19 | 2011-01-19 | Council of Scientific & Industrial Research | Anthranilic acid derivative as anticancer agent and a process for the preparation thereof |
| WO2008135232A1 (en) | 2007-05-02 | 2008-11-13 | Riccardo Cortese | Use and compositions of purine derivatives for the treatment of proliferative disorders |
| US20080293699A1 (en) | 2007-05-25 | 2008-11-27 | Burnham Institute For Medical Research | Inhibitors of thapsigargin-induced cell death |
| WO2009017838A2 (en) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| US20110124649A1 (en) | 2007-11-09 | 2011-05-26 | The Johns Hopkins University | Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders |
| US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2009143058A1 (en) | 2008-05-22 | 2009-11-26 | Allergan, Inc. | Bicyclic compounds having activity at the cxcr4 receptor |
| DE102008027574A1 (de) * | 2008-06-10 | 2009-12-17 | Merck Patent Gmbh | Neue Pyrrolidinderivate als MetAP-2 Inhibitoren |
| US8507491B2 (en) | 2008-08-25 | 2013-08-13 | Irm Llc | Compounds and compositions as hedgehog pathway inhibitors |
| WO2010030757A2 (en) | 2008-09-10 | 2010-03-18 | Kalypsys Inc. | Aminopyrimidine inhibitors of histamine receptors for the treatment of disease |
| GB0904285D0 (en) * | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| TW201038572A (en) | 2009-03-25 | 2010-11-01 | Gruenenthal Gmbh | Substituted spiro-amide compounds |
| AU2010257856A1 (en) | 2009-06-08 | 2011-11-03 | Grünenthal GmbH | Substituted benzimidazoles, benzothiazoles and benzoxazoles |
| WO2010147234A1 (en) | 2009-06-18 | 2010-12-23 | Banyu Pharmaceutical Co.,Ltd. | Diarylamide-spirodiamine derivative |
| TW201105674A (en) | 2009-07-08 | 2011-02-16 | Leo Pharma As | Novel JAK receptor and protein tyrosine kinase inhibitors and pharmaceutical use thereof |
| US8742100B2 (en) | 2009-07-30 | 2014-06-03 | National University Of Singapore | Small molecule inhibitors of isoprenylcysteine carboxyl methyltransferase with potential anticancer activity |
| JP5792171B2 (ja) | 2009-09-04 | 2015-10-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 白血病を治療するための組成物および方法 |
| ES2528441T3 (es) | 2010-02-22 | 2015-02-10 | Merck Patent Gmbh | Hetarilaminonaftiridinas |
| RU2563644C2 (ru) | 2010-08-20 | 2015-09-20 | Хатчисон Медифарма Лимитед | Пирролопиримидиновые соединения и их применения |
| WO2013019966A1 (en) | 2011-08-04 | 2013-02-07 | Allergan, Inc. | Aromatic bycyclic derivatives as cxcr4 receptor modulators |
| GB201114212D0 (en) | 2011-08-18 | 2011-10-05 | Ucb Pharma Sa | Therapeutic agents |
| AR090037A1 (es) * | 2011-11-15 | 2014-10-15 | Xention Ltd | Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio |
| CN103833759A (zh) | 2012-11-23 | 2014-06-04 | 华东理工大学 | 作为blk、flt3抑制剂的蝶啶酮衍生物及其应用 |
| GB201217704D0 (en) | 2012-10-03 | 2012-11-14 | Ucb Pharma Sa | Therapeutic agents |
| WO2014160478A1 (en) | 2013-03-13 | 2014-10-02 | Flatley Discovery Lab | Compounds and methods for the treatment of cystic fibrosis |
| JP2016512514A (ja) | 2013-03-13 | 2016-04-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法 |
| US9212180B2 (en) | 2013-06-12 | 2015-12-15 | The Regents Of The University Of Michigan | Menin-MLL inhibitors and methods of use thereof |
| ES2704704T3 (es) | 2013-12-12 | 2019-03-19 | Chong Kun Dang Pharmaceutical Corp | Nuevos derivados de azaindol como inhibidores selectivos de la histona desacetilasa (HDAC) y composiciones farmacéuticas que los comprenden |
| SG11201608242XA (en) | 2014-04-04 | 2016-10-28 | Syros Pharmaceuticals Inc | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| US20170119769A1 (en) | 2014-06-10 | 2017-05-04 | The Trustees Of The University Of Pennsylvania | Scaffolds for inhibitors of menin-mll interactions |
| WO2016040330A1 (en) * | 2014-09-09 | 2016-03-17 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| CN105732636B (zh) | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| US10588907B2 (en) | 2015-06-04 | 2020-03-17 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| DK3316969T3 (da) | 2015-07-02 | 2022-05-02 | Janssen Sciences Ireland Unlimited Co | Antibakterielle forbindelser |
| EP3394064A1 (en) | 2015-12-22 | 2018-10-31 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| TWI730032B (zh) | 2016-01-13 | 2021-06-11 | 美商必治妥美雅史谷比公司 | 作為ｒｏｃｋ抑制劑之螺庚烷水楊酸醯胺及相關化合物 |
| EP3407884A4 (en) | 2016-01-26 | 2019-09-11 | Memorial Sloan-Kettering Cancer Center | TARGETING OF CHROMATIN REGULATORS FOR THE INHIBITION OF LEUKEMOGENIC GENE EXPRESSION INNPM1 |
| MX2018011105A (es) | 2016-03-16 | 2018-11-22 | Kura Oncology Inc | Inhibidores sustituidos de menina-mll y metodos de uso. |
| WO2017161002A1 (en) | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Bridged bicyclic inhibitors of menin-mll and methods of use |
| KR20190015275A (ko) | 2016-05-02 | 2019-02-13 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 메닌 억제제로서의 피페리딘 |
| WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
| EP3805215A1 (en) | 2016-06-10 | 2021-04-14 | Vitae Pharmaceuticals, LLC | Inhibitors of the menin-mll interaction |
| WO2018024602A1 (en) | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
| TWI738864B (zh) | 2016-09-14 | 2021-09-11 | 比利時商健生藥品公司 | Ｍｅｎｉｎ-ｍｌｌ相互作用之螺二環抑制劑 |
| TWI753016B (zh) | 2016-09-14 | 2022-01-21 | 比利時商健生藥品公司 | Menin-mll相互作用之稠合二環抑制劑 |
| IL265028B (en) | 2016-09-16 | 2022-09-01 | Vitae Pharmaceuticals Llc | Inhibitors of the menin-mil interaction |
| TW201920170A (zh) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
-
2017
- 2017-03-15 MX MX2018011105A patent/MX2018011105A/es unknown
- 2017-03-15 EP EP23151871.3A patent/EP4219449A3/en active Pending
- 2017-03-15 LT LTEPPCT/US2017/022564T patent/LT3429591T/lt unknown
- 2017-03-15 BR BR112018068703-0A patent/BR112018068703B1/pt active IP Right Grant
- 2017-03-15 WO PCT/US2017/022564 patent/WO2017161028A1/en active Application Filing
- 2017-03-15 HR HRP20230537TT patent/HRP20230537T1/hr unknown
- 2017-03-15 CN CN202210112927.9A patent/CN114539284A/zh active Pending
- 2017-03-15 EP EP17767462.9A patent/EP3429591B1/en active Active
- 2017-03-15 DK DK17767462.9T patent/DK3429591T3/da active
- 2017-03-15 ES ES17767462T patent/ES2947636T3/es active Active
- 2017-03-15 PT PT177674629T patent/PT3429591T/pt unknown
- 2017-03-15 FI FIEP17767462.9T patent/FI3429591T3/fi active
- 2017-03-15 CN CN201780030597.6A patent/CN109152784B/zh active Active
- 2017-03-15 CA CA3015847A patent/CA3015847A1/en active Pending
- 2017-03-15 SG SG11201807982UA patent/SG11201807982UA/en unknown
- 2017-03-15 HU HUE17767462A patent/HUE061989T2/hu unknown
- 2017-03-15 JP JP2018544324A patent/JP6919977B2/ja active Active
- 2017-03-15 RS RS20230441A patent/RS64261B1/sr unknown
- 2017-03-15 MD MDE20190122T patent/MD3429591T2/ro unknown
- 2017-03-15 US US16/082,649 patent/US10781218B2/en active Active
- 2017-03-15 SI SI201731362T patent/SI3429591T1/sl unknown
- 2017-03-15 TW TW106108622A patent/TWI747889B/zh active
- 2017-03-15 PL PL17767462.9T patent/PL3429591T3/pl unknown
- 2017-03-15 IL IL261606A patent/IL261606B/en unknown
- 2017-03-15 AU AU2017232516A patent/AU2017232516B2/en active Active
- 2017-03-15 KR KR1020187029385A patent/KR102419531B1/ko active IP Right Grant
-
2018
- 2018-09-11 PH PH12018501952A patent/PH12018501952A1/en unknown
-
2019
- 2019-01-24 HK HK19101290.4A patent/HK1259232A1/zh unknown
-
2020
- 2020-07-30 US US16/944,040 patent/US11673898B2/en active Active
-
2021
- 2021-07-21 JP JP2021120820A patent/JP2021183609A/ja active Pending
-
2023
- 2023-06-14 CY CY20231100277T patent/CY1126066T1/el unknown
- 2023-07-13 JP JP2023115451A patent/JP2023153820A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1259232A1 (zh) | Menin-mll的取代抑制劑及其使用方法 | |
| HK1249513A1 (zh) | Kras的稠合三環抑制劑及其使用方法 | |
| IL286316A (en) | New micro-dystrophins and related method of use | |
| HK1252693A1 (zh) | Egfr抑制劑及其使用方法 | |
| HK1258821A1 (zh) | Menin-mll的橋接雙環抑制劑及其使用方法 | |
| IL267291A (en) | Actonucleotidase inhibitors and methods of using them | |
| EP3684361A4 (en) | MENINE-MLL SUBSTITUTE INHIBITORS AND METHODS OF USE | |
| IL250415B (en) | Antibodies against pd-l and methods of using them | |
| EP3510040A4 (en) | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE | |
| ZA201905677B (en) | Glycan-interacting compounds and methods of use | |
| HK1253049A1 (zh) | 糖基相互作用化合物及其使用方法 | |
| IL259801A (en) | ezh2 inhibitors and methods of using them | |
| ZA201700786B (en) | Protein kinase c inhibitors and methods of their use | |
| IL282482A (en) | Variants of protoxin-II and methods of use | |
| IL274504A (en) | 2ACSS inhibitors and methods of their use | |
| GB201609786D0 (en) | Compounds and method of use | |
| GB2562984B (en) | Hydrate inhibitors and methods of use | |
| IL282508A (en) | Variants of protoxin-II and methods of use | |
| HK1257171A1 (zh) | 間變性淋巴瘤激酶（alk）和絲氨酸富集蛋白激酶 （sppk）的抑制劑及其使用方法 | |
| HK1248684A1 (zh) | Usp7抑制劑化合物及使用方法 | |
| EP3370763A4 (en) | CD200 INHIBITORS AND METHODS OF USE | |
| IL266344A (en) | Inhibitors of mtor-deptor interactions and methods of use thereof |